The most encouraging aspect to the series of speeches the FDA's new commissioner, Mark McClellan, MD, PhD, has been giving is not what he says—we've heard most of this before—but whom he says it to: pharmaceutical investors and companies.
In February, McClellan made keynote addresses to two investor meetings in New York City outlining his plans to shorten drug...